Skip to content

Comment on Y Combinator ups the ante with bio startups for 2015parent

Comments

23 and me is an example of the least ambitious thing you could do with genomics. Honestly, I think you are being needlessly negative. There is a lack of life sciences research funding and an oversupply of life science researchers. What's the disadvantage of more biotech startups? Public-private collaborations with small nimble startups sounds like a dream come true, compared to years waiting for the wheels to turn in collaborations with big pharma.

AboutSource Built by g1lg1l

Hackerly is an independent reader for Hacker News, built on the public HN API. Not affiliated with Y Combinator.